Latest Posts

30

May 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

featured, Press release 2024
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More

22

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

featured, Press release 2024
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Try Ontosight® For Free

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the results of a pilot project carried out in cooperation with the German Cancer Society’s Working Group for Internal Oncology (AIO) under the leadership of AIO-Studien-gGmbH. The aim of the project was to investigate the feasibility and performance of modern AI-supported technologies in oncology by extracting, structuring and analyzing both care and study data using statistical tools.

The results of the pilot project showed that AI-supported data processing can be successfully used to collect clinical data and can therefore make a relevant contribution to effective clinical research, deliver precise analyzes and enable important insights.

A potential benefit is the use of this data for scientific evaluations and registry reporting. An AI model was developed to optimize data collection for the German cancer registry. This AI is intended to automatically fill data fields with patient information and thus contribute to simplifying and making the reporting process more precise.

This pilot project underlines the technical feasibility and broad application possibilities of artificial intelligence in oncology and thus marks a milestone for future medical innovations.

With AI as a central element, the PARTEX Group delivers healthcare innovations for pharma, biotech and healthcare facilities.

Read more about this news. https://www.aio-portal.de/presse.html

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing
on June 27, 2023

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…

Read More